Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
Status:
Recruiting
Trial end date:
2023-03-12
Target enrollment:
Participant gender:
Summary
To improve the efficacy of immunotherapy for cancer, recent studies focused on specific
targets to redirect the immune network toward eradicating a variety of tumors and
ameliorating the self-destructive process.
A clinically relevant immune escape mechanism in melanoma is the activation of the Programmed
cell Death-1 (PD-1) receptor on infiltrating T cells. By blocking PD-1 receptors with
anti-PD-1 monoclonal antibodies (mAbs), T-cells are unaffected by the PD-L1 expressed on
tumor cells and the patients T cells are free to respond to melanoma antigens and attack
tumor cells. So the objective of this trial is to evaluate the safety and the efficacy of a
combined therapy Nivolumab and adoptive T cell therapy in metastatic melanoma patients.